Similar articles

• Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.

  Kroboth PD, Mitchum K, Puschett JB. Kroboth PD, et al. Am J Kidney Dis. 1984 Jul;4(1):78-9. doi: 10.1016/s0272-6386(84)80032-3. Am J Kidney Dis. 1984. PMID: 6204527
• Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.

  Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, Woosley RL. Roden DM, et al. Am J Cardiol. 1980 Sep;46(3):463-8. doi: 10.1016/0002-9149(80)90016-8. Am J Cardiol. 1980. PMID: 6158263 Clinical Trial.
• [New anti-arrhythmia drug. III. Comparative studies of the effects of N-propionylprocainamide, procainamide and N-acetylprocainamide on hemodynamics and cardiac blood flow].

  Kusowska J, Polakowski P. Kusowska J, et al. Acta Pol Pharm. 1989;46(2):187-94. Acta Pol Pharm. 1989. PMID: 2483600 Polish.
• Theoretical basis for interest in acetylprocainamide and clinical experiences with this new antiarrhythmic agent.

  Drayer D, Kluger J, Reidenberg M, Lahita R. Drayer D, et al. Drug Metab Rev. 1979;10(2):239-46. doi: 10.3109/03602537908997471. Drug Metab Rev. 1979. PMID: 95247 Review.
• [Clinical pharmacology of anti-arrhythmia agents. I. Quinidine, procainamide and disopyramide].

  Witkowska M. Witkowska M. Kardiol Pol. 1981;24(7):505-17. Kardiol Pol. 1981. PMID: 7024612 Review. Polish. No abstract available.